BioSim™ anti-Infliximab (Remsima®) (Human) ELISA Kit

(No reviews yet) Write a Review
Usually Shipped in 5 Working Days
100 Assays
Storage Conditions:
Shipping Conditions:
Gel Pack
Shelf life:
12 months
Frequently bought together:


Infliximab (CT-P13) (Remsima®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNFα) in the body by binding to it and preventing it from signaling the receptors for TNFα on the surface of various cell types. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. In controlled trials, clinical response rates of 20-40% have been achieved with above-mentioned regimens in Crohn’s disease and rheumatoid arthritis. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Infliximab ELISA kit is designed to quantify/measure the antibody against Infliximab (CT-P13) (Remsima®) with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the quantitative measurement of antibody against Infliximab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of antibody against Infliximab (Remsima) in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of antibody against Infliximab (Remsima) in human serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of antibody against Infliximab (Remsima) in human serum and plasma. Detection Range: 62 - 500 ng/ml Sensitivity: 30 ng/ml Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) Cross Reactivity: Infliximab (Remsima®) infusion camouflages/masks the presence of antibody to infliximab (ATI) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATI. It is convenient to obtain blood sample just before the infusion of infliximab or at least 2 weeks after the infusion of infliximab. Recovery rate: 85 – 115% with normal human serum samples with known concentrations

View AllClose